Previous 10 | Next 10 |
Today, we do a deep dive on Epizyme for the first time since March of last year. The stock is one of the few in the market near its 52-week lows. The name has become a 'battleground stock' among analysts as well. What is ahead for Epizyme in 2021? We try to answer that...
Jaguar Health (JAGX) -16%.Foresight Autonomous Holdings (FRSX) -12%.Altimmune (ALT) -10% after FDA places hold on Altimmune's IND for COVID-19 vaccine candidate.Alibaba Group Holding (BABA) -9% after anti-monopoly probe by China.Aqua Metals (AQMS) -9%.Ocugen (OCGN)...
Epizyme (EPZM) said Boehringer Ingelheim International ((BII)) has elected to terminate a collaboration agreement between both the companies, without providing any cause for the termination, effective January 31.Under the agreement, the parties had agreed to discover, research, develop and co...
Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in a fireside chat during the Jefferies Virtua...
Image source: The Motley Fool. Epizyme Inc (NASDAQ: EPZM) Q3 2020 Earnings Call Nov 6, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Epizyme Inc (EPZM) Q3 2020 Earnings Call Transcript
Epizyme, Inc. (EPZM) Q3 2020 Results Earnings Conference Call November 6, 2020, 08:00 AM ET Company Participants Alicia Davis - Investor Relations, THRUST Strategic Communications Robert Bazemore - President and Chief Executive Officer Matthew Ros - Executive Vice President, Chief Strategy an...
Gainers: Aurora Cannabis (ACB) +82%, Sundial Growers (SNDL) +69%, Tilray (TLRY) +36%, OrganiGram Holdings Inc. (OGI) +30%, MEDNAX (MD) +19%.Losers: Assembly Biosciences (ASMB) -69%, Global Blood Therapeutics (GBT) -35%, AcelRx Pharmaceuti...
Epizyme ([[EPZM]] -23.2%) Q3 results:Revenue of $3.57M (-37.6% Y/Y) vs consensus of $5.9MNet loss: ($56.1M) (+4.1%); loss/share: ($0.55) (+5.2%); Quick Assets: $279.9M.Financial Guidance: Epizyme expects that its existing cash and equivalents will fund the company’s operations int...
Assembly Biosciences (ASMB) -55% on Q3 earnings release.Global Blood Therapeutics (GBT) -32% on Q3 earnings release.Epizyme (EPZM) -23% on Q3 earnings release.Marin Software (MRIN) -14% on Q3 earnings release.Hall of Fame Resort & Entertainment (HOF...
Epizyme (EPZM): Q3 GAAP EPS of -$0.55 beats by $0.06.Revenue of $3.57M (-37.6% Y/Y) misses by $2.32M.Press Release For further details see: Epizyme EPS beats by $0.06, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...